No Data
No Data
Septerna Discontinues Phase 1 Trial of SEP-786 for Hypoparathyroidism; Shares Fall Pre-Bell
Septerna Shares Are Trading Lower After the Company Announced the Discontinuation of Its Phase 1 Trial of SEP-786 Due to Unanticipated Bilirubin Events.
Hold Rating for Septerna, Inc. Amid Lead Program Discontinuation and Pipeline Uncertainty
Wells Fargo Downgrades Septerna After Lead Program SEP-786 Discontinued
Septerna Downgraded to Equal Weight From Overweight at Wells Fargo
Express News | Trading Halt: Halt Status Updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times
HelloHellohellohello : it will drop below 4 wait